



07-31-02

EXPRESS MAIL CERTIFICATE

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

"Express Mail" Label No. : EV 032 110 016 US

Date of Deposit : July 30, 2002

Serial No. : 10/091,609

Applicant(s) : Adnan M. M. Mjalli et al.

Filing Date : March 5, 2002


Title: : BENZIMIDAZOLE DERIVATIVES
AS THERAPEUTIC AGENTS

Examiner : Unassigned

Group Art Unit : 1626

Type of Document(s) : Transmittal Form
Information Disclosure Statement (in duplicate)
PTO/SB/08A
References: 68
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

 (signature)
Madge Leonard

Please type a plus sign (+) inside this box →


+

EV 032 110 016 US PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number



TRANSMITTAL FORM

(Do not send for all correspondence after initial filing)

		Application Number	10/091,609
		Filing Date	March 5, 2002
		First Named Inventor	Adnan M. M. Mjalli et al.
		Group Art Unit	1626
		Examiner Name	Unassigned
Total Number of Items in This Submission (including Transmittal Form)	73	Attorney Docket Number	41305-271622 (2001-07)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (in duplicate) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Express Mail Certificate – EV 032 110 016 US PTO/SB/08A References: 68 Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Cynthia B. Rothschild, Esq. Reg. No. 47,040
Signature	
Date	7/30/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service's first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 			
Typed or printed name	SENT VIA EXPRESS MAIL		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-271622
WINLIB01:957041.1

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900
PATENT

PTP 2001-07

JUL 30 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of : Adnan M. M. Mjalli et al.
Serial No. : 10/091,609
Filing Date : March 5, 2002
Title : BENZIMIDAZOLE DERIVATIVES
AS THERAPEUTIC AGENTS
Examiner : Unassigned
Group Art Unit : 1626

Assistant Commissioner of Patents
Washington, DC 20231

Sir:


INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08A. A copy of each of the references listed on the attached form is submitted herewith.

It is respectfully requested that the references listed on the attached form be expressly considered by the Examiner and be made of record in the application and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,


Cynthia B. Rothschild, Reg. No. 47,040

Date: 7/30/02

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 747-7541 Phone
(336) 607-7500 Facsimile
Attorney Docket No.: 41305-271622
41305-271622
WINLIB01:957036.1


Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

RECEIVED

Application Number 10/091,609
Filing Date March 5, 2002
First Named Inventor Adnan M.M. Mjalli
Group Art Unit 1626
Examiner Name Unassigned
Attorney Docket Number 41305-271622 (2001-07)
Express Mail Certificate EV 032 110 016 US

AUG 6 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	4,166,452		Generales, Jr.	09-04-79	
	2	4,265,874		Bonsen, et al.	05-05-81	
	3	4,356,108		Schwab, et al.	10-26-82	
	4	4,873,313		Crawford, et al.	10-10-89	
	5	5,202,424		Vlassara, et al.	04-13-93	
	6	5,585,344		Vlassara, et al.	12-17-96	
	7	5,688,653		Ulrich, et al.	11-18-97	
	8	5,864,018		Morser, et al.	01-26-99	
	9	5,939,526		Gaugler, et al.	08-17-99	
	10	6,100,098		Newkirk	08-08-00	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ² (if known)				
	11	WO	00/20458		The Trustees of Columbia University in NYC	04-13-00		✓
	12	WO	00/20621		The Trustees of Columbia University in NYC	04-13-00		✓
	13	WO	97/26913		The Trustees of Columbia University in NYC	07-31-97		✓
	14	WO	97/39121		Schering Aktiengesellschaft	10-23-97		✓
	15	WO	9739125		Schering Aktiengesellschaft	10-23-97		✓
	16	WO	98/22138		The Trustees of Columbia University in NYC	05-28-98		✓
	17	WO	99/07402		The Trustees of Columbia University in NYC	02-18-99		✓
	18	WO	99/18987		The Trustees of Columbia University in NYC	04-22-99		✓
	19	WO	99/54485		The Trustees of Columbia University in NYC	10-28-99		✓
	20	WO	95/09838		Merrell Dow Pharmaceuticals Inc.	04-13-95		✓
	21	WO	95/35279		Merrell Pharmaceuticals Inc.	12-28-95		✓
	22	WO	97/22618		Vertex Pharma- ceuticals Incorporated	06-26-97		✓
	23	WO	96/32385		Hoechst Marion Roussel Inc.	10-17-96		✓
	24	WO	99/50230		Vertex Pharma- ceuticals Incorporated	10-07-99		✓

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number 10/091,609
Filing Date March 5, 2002
First Named Inventor Adnan M.M. Mjalli
Group Art Unit 1626
Examiner Name Unassigned
Attorney Docket Number 41305-271622 (2001-07)
Express Mail Certificate EV 032 110 016 US

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

25	GB	2 005 674	Carlo Erba S.p.A.	04-25-79	✓
26	WO	98/33492	Fox Chase Cancer Center	08-06-98	✓
27	WO	99/25690	University of Kansas Medical Center	05-27-99	✓
29	WO	01/12598	Trustees of Columbia Univ. in NYC	02-22-01	✓

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	29	Albercio, F. & Carpino, L.A., "Coupling Reagents and Activation" <i>Methods in Enzymology</i> 289:104-126, Academic Press, San Diego (1997)	✓
	30	Barton, J.W., "In Protection of N-H Bonds and NR ₃ " <i>Protective Groups in Organic Chemistry</i> , J.F.W. McOmie, ED., Plenum Press, New York, NY (1973)	✓
	31	Berge, S.M., et al., "Pharmaceutical Salts" <i>Journal of Pharmaceutical Sciences</i> 66:1-19 (1977)	✓
	32	Chitaley, K., et al., "Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway" <i>Nature Medicine</i> 7:119-122 (2002)	✓
	33	Degenhardt, T.P., et al., "Chemical Modification of Proteins by Methylglyoxal" <i>Cell Mol. Biol.</i> , 44:1139-1145 (1998)	✓
	34	Dyer, D.G., et al., "Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging" <i>J. Clin. Invest.</i> , 91:2463-2469 (1993)	✓
	35	Dyer, D.G., et al., "Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose" <i>J. Biol. Chem.</i> , 266:11654-11660 (1991)	✓
	36	Greene, T.W., "Protection for the Amino Group" <i>Protective Groups in Organic Synthesis</i> , John Wiley and Sons, New York, NY, Chapter 7 (1981)	✓
	37	Hammes, H.P., et al., "Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product N ^ε -(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations" <i>Diabetologia</i> , 42:603-607 (1999)	✓
	38	Hoffman, M.A., et al., "RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides" <i>Cell</i> , 97:889-901 (1999)	✓
	39	Hori, O., et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding site for Amphoterin" <i>J. Biol. Chem.</i> , 270:25752-761 (1995)	✓
	40	Huttunen, H.J., et al., "Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways" <i>J. Biol. Chem.</i> 274(28):19919-24 (1999)	✓
	41	Kumar, S.R., et al., "RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloid β_{1-40} Peptide" <i>Neurosci. Program</i> , 141-#255.19 (2000)	✓

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

RECEIVED

Substitute for form 1449APTO

Complete if Known


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 110 016 US

AUG 06 2002

TECH CENTER 1600/2900



42	Leder, A. et al., "v-HA-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid" <i>Proc. Natl. Acad. Sci., USA</i> , 87:9178-9182 (1990)	✓
43	Li, J. et al., "Sp1-Binding elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells." <i>J. Biol. Chem.</i> , 273:30870-30878 (1998)	✓
44	Li, J. et al., "Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products," <i>J. Biol. Chem.</i> , 272:16498-16506 (1997)	✓
45	Lugering, N. et al., "The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" <i>Eur. J. Clin. Invest.</i> , 25:659-664 (1995)	✓
46	Miyata, T. et al., "β ₂ -Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" <i>J. Clin. Invest.</i> , 92:1243-1252 (1993)	✓
47	Miyata, T. et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β ₂ Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway" <i>J. Clin. Invest.</i> , 98:1088-1094 (1996)	✓
48	Neeper, M., et al., "Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins" <i>J. Biol. Chem.</i> , 267:14998-15004 (1992)	✓
49	Parkkinen, J. et al., "Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides" <i>J. Biol. Chem.</i> , 268:19726-19738 (1993)	✓
50	Rammes, A. et al., "Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway" <i>J. Biol. Chem.</i> , 272:9496-9502 (1997)	✓
51	Rauvala, H. et al., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons" <i>J. Biol. Chem.</i> , 262:16625-16635 (1987)	✓
52	Reddy, S. et al., "N ^ε -(Carboxymethyl) Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" <i>Biochem.</i> , 34:10872-10878 (1995)	✓
53	Schafer, B.W., et al., "The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology" <i>TIBS</i> , 21:134-140 (1996)	✓
54	Schleicher, E.D., et al., "Increased Accumulation of the Glycooxidation Product N ^ε -(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging" <i>J. Clin. Invest.</i> , 99(3):457-468 (1997)	✓
55	Schmidt, A.M. et al., "The Dark Side of Glucose" <i>Nature Med.</i> , 1:1002-1004 (1995)	✓
56	Schmidt, A.M., et al., "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications:" <i>Supplement to Circulation</i> Vol. 96, #194 (1997)	✓
57	Taguchi, A. et al., "Blockade of RAGE—Amphoterin Signalling Suppresses Tumour Growth and Metastases" <i>Nature</i> , 405:354-360 (2000)	✓

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

RECEIVED

Application Number 10/091,609
Filing Date March 5, 2002
First Named Inventor Adnan M.M. Mjalli
Group Art Unit 1626
Examiner Name Unassigned
Attorney Docket Number 41305-271622 (2001-07)
Express Mail Certificate EV 032 110 016 US

AUG 6 2002

TECH CENTER 1600/2900

58	Tanaka, N., et al., "The Receptor for Advanced Glycation End Products is Induced by the Glycation Products Themselves and Tumor Necrosis Factor- α through Nuclear Factor- κ B, and by 17 β -Estradiol through Sp-1 in Human Vascular Endothelial Cells" <i>J. Biol. Chem.</i> , 275:25781-25790 (2000)	✓
59	Teillet et al., "Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats" <i>J. Am. Soc. Nephrol.</i> , 11:1488-1497 (2000)	✓
60	Vlassara, H., "Advanced Glycation End-Products and Atherosclerosis" <i>The Finnish Medical Society DUODECIM, Ann. Med.</i> , 28:419-426 (1996)	✓
61	Wautier et al., "Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy: Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability in Diabetic Rats" <i>J. Clin. Invest.</i> , 97:238-243 (1996)	✓
62	Yan, S.-D., et al., "RAGE and Amyloid- β Peptide Neurotoxicity in Alzheimer's Disease" <i>Nature</i> 382:685-691 (1996)	✓
63	Yan, S.-D., et al., "An Intracellular Protein That Binds Amyloid- β Peptide and Mediates Neurotoxicity in Alzheimer's Disease" <i>Nature</i> , 389:689-695, (1997)	✓
64	Yan, S.-D. et al., "Amyloid- β Peptide—Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" <i>Proc. Natl. Acad. Sci., USA</i> , 94:5296-5301 (1997)	✓
65	Yan, S.-D. et al., "Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis" <i>Nat. Med.</i> 6:643-651 (2000)	✓
66	Yan, S.-D. et al., "Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation Endproducts With Their Receptors Binding Proteins" <i>J. Biol. Chem.</i> 269:9889-9897 (1994)	✓
67	Zimmer, D. et al., The S100 Protein Family: History, Function, and Expression" <i>Brain Res. Bull.</i> 37:417-429 (1995)	✓
68	International Search Report for PCT/US 01/17251 dated 8/14/01	✓

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-252461

WINLIB01:956770.1